NEW YORK (GenomeWeb News) – Nuclea Biotechnologies has raised $1.1 million toward a targeted $2.5 million financing round.

The company disclosed the raise in a document filed with the US Securities and Exchange Commission this week. A spokesman told GenomeWeb Daily News that the Pittsfield, Mass.-based firm plans to close the $2.5 million round at the end of next month. He said that Nuclea would not be disclosing who the investors are or how the funds from the financing would be used until then.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.